Drug Trial Radar · NCT01518166
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
Last checked: Nov 19, 2026Latest source record: Jan 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
May 2006
Primary completion
Apr 2007
Study completion Apr 2007
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
Conditions
- Diabetes
- Healthy
Interventions
liraglutideDrug
Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
placeboDrug
Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
atorvastatinDrug
One single dose of 40 mg. Tablet
lisinoprilDrug
One single dose of 20 mg. Tablet
griseofulvinDrug
One single dose of 500 mg. Tablet
digoxinDrug
One single dose of 1 mg. Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve of atorvastatin
- Area under the curve of lisinopril
- Area under the curve of griseofulvin
- Area under the curve of digoxin
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.